Drugs / PF-07985631
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07235150 | Dec 2025 → Aug 2027 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT06994897 | Aug 2025 → Dec 2027 expected | — | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07985631 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06994897 ↗ |
| Route | Intravenous | “Experimental Pfizer compound which will be SC or IV” NCT06994897 ↗ |
| Route | Subcutaneous | “Experimental Pfizer compound which will be SC or IV” NCT06994897 ↗ |